-
DEPARTMENT OF HEALTH
NOTICE OF FINAL RULEMAKING
The Director of the Department of Health, pursuant to the authority set forth in § 201(a) of the District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.01(a) (2012 Repl.)) and Mayor's Order 98-49, dated April 15, 1998, hereby gives notice of the adoption of the following amendments to Chapter 12 (Controlled Substances Act Rules) of Subtitle B (Public Health & Medicine) of Title 22 (Health) of the District of Columbia Municipal Regulations (DCMR).
The final rules amend the list of drugs on Schedules I through V.
A Notice of Emergency and Proposed Rulemaking was published June 27, 2014, at 61 DCR 6518. No comments were received in response to the Notice of Emergency and Proposed rulemaking, and no changes have been to the rules. The Director took final action to adopt the rules on September 24, 2014, and they will become effective upon publication of this Notice of Final Rulemaking in the D.C. Register.
Chapter 12, CONTROLLED SUBSTANCES ACT RULES, of Subtitle B, PUBLIC HEALTH & MEDICINE, of Title 22, HEALTH, of the DCMR is amended to read as follows:
CHAPTER 12 CONTROLLED SUBSTANCES ACT RULES
1200 PURPOSE
1200.1 This chapter shall comprise all the enumerated schedules of controlled substances under the District of Columbia Uniform Controlled Substances Act of 1981 (Act), effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.01), and all final rulemakings made by the Mayor or designee that add, delete, or reschedule a controlled substance under the authority of Section 201 of the Act (D.C. Official Code § 48-902.01).
1201 SCHEDULE I ENUMERATED
1201.1 The controlled substances listed in this section are included in Schedule I of the Act unless removed therefrom pursuant to Section 201 of the Act:
(a) Opiates: Unless specifically excepted or unless listed in another schedule, any of the following opiates including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
(1) 1-Methyl-4-phenyl-4-propionoxypiperidine (MPPP);
(2) 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
(3) 3-Methylfentanyl;
(4) 3-Methylthiofentanyl;
(5) Acetyl-Alpha-Methylfentanyl;
(6) Acetylmethadol;
(7) Allylprodine;
(8) Alphacetylmethadol except Levo-alphacetylmethadol
(9) Alphameprodine;
(10) Alphamethadol;
(11) Alpha-Methylfentanyl;
(12) Alpha-Methylthiofentanyl;
(13) Benzethidine;
(14) Betacetylmethadol;
(15) Beta-hydroxyfentanyl;
(16) Beta-hydroxy-3-Methylfentanyl;
(17) Betameprodine;
(18) Betamethadol;
(19) Betaprodine;
(20) Clonitazene;
(21) Dextromoramide;
(22) Diampromide;
(23) Diethylthiambutene;
(24) Difenoxin;
(25) Dimenoxadol;
(26) Dimepheptanol;
(27) Dimethylthiambutene;
(28) Dioxaphetyl butyrate;
(29) Dipipanone;
(30) Ethylmethylthiambutene;
(31) Etonitazene;
(32) Etoxeridine;
(33) Furethidine;
(34) Hydroxypethidine;
(35) Ketobemidone;
(36) Levomoramide;
(37) Levophenacylmorphan;
(38) Morpheridine;
(39) Noracymethadol;
(40) Norlevorphanol;
(41) Normethadone;
(42) Norpipanone;
(43) Para-fluorofentanyl;
(44) Phenadoxone;
(45) Phenampromide;
(46) Phenomorphan;
(47) Phenoperidine;
(48) Piritramide;
(49) Proheptazine;
(50) Properidine;
(51) Propiram;
(52) Racemoramide;
(53) Thiofentanyl;
(54) Thiophene;
(55) Tilidine; and
(56) Trimeperidine;
(b) Opium Derivates: Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Diacetylmorphine (heroin);
(9) Dihydromorphine;
(10) Drotebanol;
(11) Etorphine (except hydrochloride salt);
(12) Hydromorphinol;
(13) Methyldesorphine;
(14) Methyldihydromorphine;
(15) Morphine methylbromide;
(16) Morphine methylsulfonate;
(17) Morphine-N-Oxide;
(18) Myrophine;
(19) Nicocodeine;
(20) Nicomorphine;
(21) Normorphine;
(22) Pholcodine; and
(23) Thebacon;
(c) Hallucinogenic Substances: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):
(1) 1-[1-(2-Thienyl)cyclohexyl]piperidine;
(2) 1- [1-(2-thienyl)cyclohexyl]pyrrolidine;
(3) 1-(1-Phenylcyclohexyl)-pyrrolidine,Pyrrolidine analog of phencyclidine, PCPy, PHP;
(4) (2C-C) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine;
(5) (2C-D) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;
(6) (2C-E) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;
(7) (2C-H) 2-(2,5-Dimethoxyphenyl)ethanamine;
(8) (2C-I) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine;
(9) (2C-N) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
(10) (2C-P) 2-(2,5-Dimethoxy-4(n)-propylphenyl)ethanamine;
(11) (2C-T-2) 2-[4-(ethylthio)-2,5-dimethoxyphenyl)ethanamine;
(12) (2C-T-4)2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine;
(13) (2C-T-7) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine);
(14) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe);
(15) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine 25C-NBOMe); and
(16) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);
(17) 2,5-Dimethoxyamphetamine;
(18) 2,5-Dimethoxy-4-ethylamphetamine;
(19) 3,4-Methylenedioxymethamphetamine;
(20) 3,4-Methylenedioxyamphetamine;
(21) 3,4-Methylenedioxy-N-ethylamphetamine;
(22) 3,4,5-Trimethoxyamphetamine;
(23) 4-Bromo-2,5-dimethoxy-amphetamine;
(24) 4-Bromo-2,5-dimethoxyphenethylamine;
(25) 4-Methoxyamphetamine;
(26) 4-Methylaminorex;
(27) 4-Methyl-2,5-dimethoxyamphetamine;
(28) 5-flouro-UR-144 and XLR11[1-(5-Fluoro-pentyl)1Hindol-3-yl](2,2,3,3- tetramethylcyclopropyl)methanone;
(29) 5-Methoxy-3,4-methylenedioxyamphetamine;
(30) 5-Methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
(31) 5-Methoxy-N,N-dimethyltryptamine;
(32) Bufotenine;
(33) Diethyltryptamine;
(34) Dimethyltryptamine;
(35) N-Ethyl-1-phenylcyclohexylamine;
(36) Ibogaine;
(37) Lysergic acid diethylamide;
(38) Mescaline;
(39) N-Ethyl-1-phenylcyclohexylamine;
(40) N-Ethyl-3-piperidyl benzilate;
(41) N-Methyl-3-piperidyl benzilate;
(42) Parahexyl--7374; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6Hdibenzo[b,d]pyran; Synhexyl;
(43) Peyote;
(44) Psilocybin;
(45) Psilocyn; and
(46) Thiophene analog of phencyclidine;
(d) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, or mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system including its salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible, within the specific chemical designation:
(1) Gamma-Hydroxybutyric Acid [other names include GHB; gamma- hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium xybutyrate];
(2) Mecloqualone; and
(3) Methaqualone;
(e) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Alpha-ethyltryptamine;
(2) Alpha-methyltryptamine;
(3) Aminorex;
(4) Cathinone;
(5) Fenethylline;
(6) Mephedrone (4-methyl-N-methylcathinone);
(7) Methcathinone;
(8) Methylenedioxypyrovalerone (MDPV);
(9) Methylone;
(10) N-Benzylpiperazine;
(11) N-ethylamphetamine;
(12) N-Hydroxy-3,4-methylenedioxyamphetamine; and
(13) N,N-Dimethylamphetamine; and
(14) 4-methyl-N-ethylcathinone (“4-MEC”)
(15) 4-methyl-alpha-pyrrolidinopropiophenone (“4-MePPP”)
(16) Alpha-pyrrolidinopentiophenone (“α-PVP”)
(17) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (“butylone”)
(18) 2-(methylamino)-1-phenylpentan-1-one (“pentedrone”)
(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (“pentylone”)
(20) 4-fluoro-N-methylcathinone (“4-FMC”)
(21) 3-fluoro-N-methylcathinone (“3-FMC”)
(22) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (“naphyrone”)
(23) Alpha-pyrrolidinobutiophenone (“α-PBP”)
(f) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):
(1) Classified Synthetic Cannabinoids:
(A) Adamantoylindoles or adamantoylindazoles, including adamantyl carboxamide indoles and adamantyl carboxamide indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl)indazole, 3-(2-adamantoyl)indole, N-(1-adamantyl)-1H-indole-3-carboxamide, or N-(1-adamantyl)-1H-indazole-3-carboxamide by substitution at the nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including the following: 2NE1, 5F-AKB-48, AB-001, APINACA and AKB-48, AM-1248, JWH-018 adamantyl carboxamide, STS-135;
(B) Benzoylindoles - any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following: AM-630, AM-661, AM-679, AM-694, AM-1241, AM-2233, RCS-4 or SR-19, WIN 48,098 (Pravadoline);
(C) Cyclohexylphenols - any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent, including, but not limited to, the following: CP 47,497, CP 47,497 C8 homologue, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol;
(D) Cyclopropanoylindoles – any compound structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent;
(E) Naphthoylindoles – any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2201, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55,212;
(F) Naphthoylnaphthalenes – any compound structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent, including CB-13;
(G) Naphthoylpyrroles - any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;
(H) Naphthylmethylindenes - any compound containing a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-171, JWH-176, JWH-220;
(I) Naphthylmethylindoles – any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199;
(J) Phenylacetylindoles - any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following: Cannabipiperidiethanone, JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, or SR-18;
(K) Quinolinylindolecarboxylates – any compound structurally derived from quinolin-8-yl-1H-indole-3-carboxylate by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent, including the following: BB-22, 5-Fluoro-PB-22, and PB-22;
(L) Tetramethylcyclopropanoylindoles – any compound structurally derived from 3-tetramethylcyclopropanoylindole, 3-(1-tetramethylcyclopropyl)indole, 3-(2,2,3,3-tetramethylcyclopropyl)indole or 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropanoyl ring to any extent, including the following: 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, and XLR11; and
(M) Tetramethylcyclopropane-thiazole carboxamides – any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including A-836,339; and
(2) Unclassified Synthetic Cannabinoids:
(A) AM-087 (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(B) AM-356 (methanandamide);
(C) (5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'-hydroxy-2'-propylamide;
(D) AM-411(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(E) AM-855(4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8, 9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol;
(F) AM-905(6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-
(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
(G) AM-906(6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-
(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
(H) AM-2389(6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-
6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol;
(I) BAY38-7271(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate;
(J) CP 50,556-1 (Levonantradol);
(K) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6, 6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-;
(L) octahydrophenanthridin-1-yl] acetate; or [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate;
(M) HU-210(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-
3-;
(N) (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; or [(6aR,10aR)-9-(hydroxymethyl) -6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol; or 1,1-Dimethylheptyl- 11-hydroxytetrahydrocannabinol;
(O) HU-211 (Dexanabinol);
(P) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or (6aS,10aS)-9-(hydroxymethyl) -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(Q) HU-2433-dimethylheptyl-11- hydroxyhexahydrocannabinol;
(R) HU-308[(91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol;
(S) HU-3313-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;
(T) JTE-907N-(benzol[1,3]dioxol-5-ylmethyl) -7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide;
(U) JWH-051((6aR,10aR)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol;
(V) JWH-057(6aR,10aR)-3-(1,1-dimethylheptyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran;
(W) JWH-133(6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
(X) JWH-359 (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene;
(Y) URB-597[3-(3-carbamoylphenyl)phenyl] -N-cyclohexylcarbamate;
(Z) URB-602 [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;
(AA) URB-7546-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one;
(BB) URB-937 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate;
(CC) WIN 55,212-2(R)-(+)-[2,3-dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or [2,3-Dihydro-5-methyl- 3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone;
(DD) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); and
(EE) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole).
(FF) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (“PB-22”; QUPIC)
(GG) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (“5-fluoro-PB-22”; 5F-PB-22)
(HH) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (“AB-FUBINACA
(II) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (“ADB-PINACA”)
1202 SCHEDULE II ENUMERATED
1202.1 The controlled substances listed in this section are included in Schedule II of the Act unless removed therefrom pursuant to Section 201 of the Act:
(a) Unless specifically excepted or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis;
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextophan, nalbuphine, naltrexone, and their respective salts, but including the following:
(A) Codeine;
(B) Ethylmorphine;
(C) Etorphine Hydrochloride;
(D) Granulated opium;
(E) Hydrocodone;
(F) Tincture of opium;
(G) Hydromorphone;
(H) Metopon;
(I) Morphine;
(J) Opium extracts;
(K) Opium fluid extracts;
(L) Oripavine;
(M) Oxycodone;
(N) Oxymorphone;
(O) Powdered opium;
(P) Raw opium; and
(Q) Thebaine;
(2) Opium: Any salt, compound, derivative, or preparation thereof that is chemically equivalent or identical with any of the substances referred to in subparagraph (1) of this paragraph, but not including the isoquinoline alkaloids of opium;
(3) Opium poppy or poppy straw;
(4) Coca leaves, except coca leaves or extracts of coca leaves from which cocaine, ecgonine, or derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric isomers, salts of isomers; or any compound, mixture, or preparation that contains any substance referred to in this paragraph;
(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy); and
(6) Hashish;
(b) Opiates: Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan excepted:
(1) 4-anilino-N-phenethyl-4-piperidine (ANPP);
(2) Alfentanil;
(3) Alphaprodine;
(4) Anileridine;
(5) Bezitramide;
(6) Bulk Dextropropoxyphene (non-dosage form);
(7) Carfentanil;
(8) Dihydrocodeine;
(9) Dihydroetorphine;
(10) Diphenoxylate;
(11) Fentanyl;
(12) Isomethadone;
(13) Levo-alphacetylmethadol [Some other names: levo-alpha- acetylmethadol, levomethadyl acetate, LAAM] ;
(14) Levomethorphan;
(15) Levorphanol;
(16) Metazocine;
(17) Methadone;
(18) Methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(19) Moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
(20) Pethidine (meperidine);
(21) Pethidine-Intermediate-A, 4-cyano-1-methyl-4- phenylpiperidine; (Meperidine intermediate-A)
(22) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine- 4-carboxylate; (Meperidine intermediate-B);
(23) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine- 4-carboxylic acid; (Meperidine intermediate-C)
(24) Phenazocine;
(25) Piminodine;
(26) Racemethorphan;
(27) Racemorphan;
(28) Remifentanil
(29) Sufentanil; and
(30) Tapentadol;
(c) Stimulants: Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system:
(1) Amphetamines, its salts, optical isomers, and salts of its optical isomers;
(2) Biphetamine
(3) Eskatrol
(4) Lisdexamfetamine
(5) Methylphenidate and its salts;
(6) Methamphetamine, its salts, isomers, and salts of isomers; and
(7) Phenmetrazine and its salts;
(d) Immediate precursors: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any
(1) Amphetamine/methamphetamine immediate precursor: phenylacetone (other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone);
(2) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperidine (ANPP); and
(e) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Amobarbital;
(2) Glutethimide.
(3) Pentobarbital; and
(4) Secobarbital; and
(f) Hallucinogenic substances:
(1) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine;
(B) 1-piperidinocyclohexanecarbonitrile (PCC); and
(2) Nabilone.
1203 SCHEDULE III ENUMERATED
1203.1 The controlled substances listed in this section are included in Schedule III of the Act unless removed therefrom pursuant to Section 201 of the Act:
(a) Schedule III shall consist of the following controlled substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section:
(1) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric), and salts, isomers, and salts of isomers is possible within the specific chemical designation:
(A) The compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971 as excepted compounds under Title 21 § 1308.32 of the Code of Federal Regulations (C.F.R.), and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;
(B) Benzphetamine;
(C) Chlorphentermine;
(D) Clortermine;
(E) Mazindol; and
(F) Phendimetrazine;
(2) Depressants: Unless listed in another schedule, any material compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with depressant effect on the central nervous system:
(A) Any compound, mixture, or preparation containing:
(i) Amobarbital;
(ii) Aprobarbital;
(iii) Butabarbital;
(iv) Butabarbital (secbutabarbital);
(v) Butalbital;
(vi) Butobarbital (butethal);
(vii) Secobarbital;
(viii) Pentobarbital; or any salt thereof and one (1) or more other active medicinal ingredients which are not listed in any schedule;
(ix) Perampanel;
(x) Talbutal;
(xi) Thiamylal;
(xii) Thiopental; and
(xiii) Vinbarbital;
(B) Any suppository dosage form containing:
(i) Amobarbital;
(ii) Aprobarbital;
(iii) Butabarbital;
(iv) Butabarbital (secbutabarbital);
(v) Butalbital;
(vi) Butobarbital (butethal);
(vii) Pentobarbital; or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;
(viii) Secobarbital; and
(ix) Vinbarbital; and
(C) Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid:
(i) Chlorhexadol;
(ii) Embutramide;
(iii) Any drug product containing gamma-hydroxybutric acid including its salts, isomers, and salts of isomers.
(iv) Ketamine;
(v) Lysergic acid;
(vi) Lysergic acid amide;
(vii) Methyprylon;
(viii) Sulfondiethylmethane;
(ix) Sulfonethylmethane;
(x) Sulfonmethane; and
(xi) Tiletamine & Zolazepam Combination Product;
(3) Nalorphine;
(4) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(A) Not more than one and eight-tenths (1.8) grams of codeine per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
(B) Not more than one and eight-tenths (1.8) grams of codeine per one hundred (100) milliliters or not more than ninety (90) milligrams dosage unit, with one (1) or more active non-narcotic ingredients in recognized therapeutic amounts;
(C) Not more than three hundred (300) milligrams of dihydrocodeinone per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with a 4-fold or greater quantity of an isoquinoline alkaloid of opium;
(D) Not more than three hundred (300) milligrams dihydrocodeine per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts;
(E) Not more than one and eight-tenths (1.8) grams of dihydrocodeine per milliliters or not more than ninety (90) milligrams per dosage unit, with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts;
(F) Codeine and isoquinoline alkaloid ninety (90) milligrams per dosage unit;
(G) Codeine combination product ninety (90) milligrams per dosage unit;
(H) Dihydrocodeine combination product ninety (90) milligrams per dosage unit;
(I) Ethylmorphine combination product fifteen (15) milligrams per dosage unit;
(J) Hydrocodone and isoquinoline alkaloid less than fifteen (15) milligrams per dosage unit;
(K) Hydrocodone combination product less than fifteen (15) milligrams per dosage unit;
(L) Not more than three hundred (300) milligrams of ethylmorphine per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with one (1) or more ingredients in recognized therapeutic amounts;
(M) Not more than five hundred (500) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams or not more than twenty-five (25) milligrams per dosage unit, with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts;
(N) Opium combination product twenty-five (25) milligrams per dosage unit;
(O) Not more than fifty (50) milligrams of morphine per one hundred (100) milliliters or per one hundred (100) grams with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts; and
(P) Any material, compound, mixture, or preparation containing Buprenorphine or its salts;
(5) Anabolic Steroids: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, drug, or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progesterons, and corticosteroids) that promotes muscle growth and includes:
(A) Boldenone (17beta-hydroxyandrost-1,4- diene-3-one);
(B) Chlortestosterone (4-chlortestosterone);
(C) Clostebol(4-chloro-17beta-hydroxyandrost- 4-en-3-one);
(D) Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);
(E) Delta1-dihydrotestosterone (17beta-hydroxy-5alpha androst-1-en-3-one);
(F) Drostanolone(17beta-hydroxy-2alpha-methyl- 5alphaandrostan-3-one);
(G) Ethylestrenol(17alpha-ethyl-17beta-hydroxyestr- 4-ene);
(H) Fluoxymesterone (9-fluoro-17alpha-methy 11beta,17beta- dihydroxyandrost-4-en-3-one);
(I) Formebulone (formebolone);(2-formyl-17alpha- methyl11alpha,17beta-dihydroxyandrost-1,4-dien-3-one);
(J) Furazabol(17alpha-methyl- 17betahydroxyandrostano [2,3-c]-furazan);
(K) Mesterolone; (1alpha-methyl-17beta-hydroxy- 5alphaandrostan-3-one);
(L) Methandienone(17alpha-methyl- 17betahydroxyandrost- 1,4-diene-3-one);
(M) Methandriol (17alpha-methyl-3beta, 17betadihydroxyandrost-5-ene) (a.k.a. Methandrostenolone);
(N) Methenolone (1-methyl-17beta-hydroxy- 5alpha-androst1-en-3-one);
(O) Methyltestosterone (17alpha-methyl- 17betahydroxyandrost- 4-en-3-one);
(P) Mibolerone (7alpha,17alpha-dimethyl- 17betahydroxyestr- 4-en-3-one);
(Q) Nandrolone (17beta-hydroxyestr-4-en-3-one);
(R) Norethandrolone (17alpha-ethyl-17beta-hydroxyestr - 4en-3-one);
(S) Oxandrolone (17alpha-methyl-17beta-hydroxy-
2-oxa5alpha-androstan-3-one);
(T) Oxymesterone (17alpha-methyl-4, 17betadihydroxyandrost-4-en-3-one);
(U) Oxymetholone (17alpha-methyl-2- hydroxymethylene17beta-hydroxy-5alpha-androstan-3-one);
(V) Stanolone;
(W) Stanozolol (17alpha-methyl-17beta-hydroxy-5alpha
androst-2-eno[3,2-c]-pyrazole);
(X) Testolactone (13-hydroxy-3-oxo- 13,17-secoandrosta 1,4-dien-17-oic acid lactone);
(Y) Testosterone (17beta-hydroxyandrost-4-en-3-one);
(Z) Trenbolone (17beta-hydroxyestr-4,9,11-trien-3- one);
(AA) 13β-ethyl-17β-hydroxygon-4-en-3-one;
(BB) 17α-methyl-3α,17β-dihydroxy-5a-androstane;
(CC) 17α-methyl-3β,17β-dihydroxy-5a-androstane;
(DD) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;
(EE) 17α-methyl-4-hydroxynandrolone (17α-methyl-4- hydroxy-17β-hydroxyestr-4-en-3-one);
(FF) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (a.k.a. '17-α-methyl-1-testosterone');
(GG) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
(HH) 19-nor-4-androstenediol (3α, 17β-dihydroxyestr- 4-ene);
(II ) 19-nor-4-androstenediol (3β, 17β-dihydroxyestr- 4-ene);
(JJ) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
(KK) 19-nor-5-androstenediol (3α, 17β-dihydroxyestr- 5-ene);
(LL) 19-nor-5-androstenediol (3β, 17β-dihydroxyestr- 5-ene);
(MM) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
(NN) 1-androstenediol (3α,17β-dihydroxy-5α-androst- 1-ene);
(OO) 1-androstenediol (3β,17β-dihydroxy-5α-androst- 1-ene);
(PP) 1-androstenedione ([5α]-androst-1-en-3,17-dione);
(QQ) 3α,17β-dihydroxy-5a-androstane;
(RR) 3β,17-dihydroxy-5a-androstane;
(SS) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene);
(TT) 4-androstenedione (androst-4-en-3,17-dione);
(UU) 4-dihydrotestosterone (17β-hydroxy-androstan- 3-one);
(VV) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy- estr-4-en-3-one);
(WW) 4-hydroxytestosterone (4,17β-dihydroxy-androst- 4-en-3-one);
(XX) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene);
(YY) 5-androstenedione (androst-5-en-3,17-dione);
(ZZ) Androstanedione 5α-androstan-3,17-dione;
(AAA) Bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
(BBB) Boldione (androsta-1,4-diene-3,17-dione);
(CCC) Calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
(DDD) Desoxymethyltestosterone (17α-methyl-5α- androst-2-en-17β-ol) (a.k.a. 'madol');
(EEE) Furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]-furazan);
(FFF) Mestanolone (17α-methyl-17β-hydroxy- 5-androstan-3-one);
(GGG) Methasterone (2α,17α-dimethyl-5α-androstan- 17β-ol-3-one);
(HHH) Methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);
(III) Methyltrienolone (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one);
(JJJ) Norbolethone (13β, 17α-diethyl-17β-hydroxygon- 4-en-3-one);
(KKK) Norclostebol (4-chloro-17β-hydroxyestr- 4-en-3-one);
(LLL) Normethandrolone (17α-methyl-17β-hydroxyestr- 4-en-3-one);
(MMM) Prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole);
(NNN) Stenbolone (17β-hydroxy-2-methyl-[5α]-androst-1-en-3-one);
(OOO) Tetrahydrogestrinone (13β, 17α-diethyl-17β-hydroxygon- 4,9,11-trien-3-one)
(PPP) Δ1-dihydrotestosterone (a.k.a.'1-testosterone') (17β-hydroxy-5α-androst-1-en-3-one); and
(QQQ) Any salts, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except the term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses or distributes that steroid for human use the person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph.,
(6) Hallucinogenic substances;
(7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product. [Some other names for dronabinol: 6aR-trans)-6a,7,8,10a-tetrahydro- 6,6,9- trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-o1] or (-)-delta-9-(trans)-tetrahydrocannabinol]; and
(8) Cannabis.
(b) The Mayor may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiates the potential for abuse of the substances that have a stimulant or depressant effect on the central nervous system.
1204 SCHEDULE IV ENUMERATED
1204.1 The controlled substances listed in this section are included in Schedule IV of the Act unless removed therefrom pursuant to Section 201 of the Act:
(a) Schedule IV shall consist of the following controlled substances:
(1) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(A) Alfaxalone;
(B) Alprazolam;
(C) Barbital;
(D) Bromazepam;
(E) Camazepam;
(F) Chloral betaine;
(G) Chloral hydrate;
(H) Chlordiazepoxide;
(I) Clobazam;
(J) Clonazepam;
(K) Clorazepate;
(L) Clotiazepam;
(M) Cloxazolam;
(N) Delorazepam;
(O) Diazepam;
(P) Dichloralphenazone;
(Q) Estazolam;
(R) Ethyl loflazepate;
(S) Ethchlorvynol;
(T) Ethinamate;
(U) Fludiazepam;
(V) Flunitrazepam;
(W) Flurazepam;
(X) Fospropofol;
(Y) Halazepam;
(Z) Haloxazolam;
(AA) Ketazolam;
(BB) Loprazolam;
(CC) Lorazepam;
(DD) Lormetazepam;
(EE) Mebutamate;
(FF) Medazepam;
(GG) Meprobamate;
(HH) Methohexital;
(II) Methylphenobarbital (mephobarbital);
(JJ) Midazolam;
(KK) Nimetazepam;
(LL) Nitrazepam;
(MM) Nordiazepam;
(NN) Oxazepam;
(OO) Oxazolam;
(PP) Paraldehyde;
(QQ) Petrichloral;
(RR) Phenobarbital;
(SS) Pinazepam;
(TT) Prazepam;
(UU) Quazepam;
(VV) Temazepam;
(WW) Tetrazepam; and
(XX) Triazolam;
(2) Fenfluramine: Any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, (whether optical, position, or geometric), and salts of such isomers, whenever the existence of the salts, isomers, and salts of isomers is possible: Fenfluramine;
(3) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of the salts, isomers and salts of isomers is possible within the specific chemical designation:
(A) Cathine;
(B) Clortermine;
(C) Dexfenfluramine;
(D) Diethylpropion;
(E) Fencamfamin;
(F) Fenproporex;
(G) Lorcaserin;
(H) Mazindol;
(I) Mefenorex;
(J) Modafinil;
(K) Pemoline (including organometallic complexes and chelates thereof);
(L) Phentermine;
(M) Pipradrol;
(N) Sibutramine; and
(AA) SPA;
(4) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances, including its salts:
(A) Butorphanol;
(B) Dextropropoxyphene (Alpha-(+)-4-demethylamino-1), 2-diphenyl-1-3-methyl-2-propionoxybutane; and
(D) Pentazocine;
(5) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof of not more than one (1) milligram of difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;
(6) Carisoprodol;
(7) Zaleplon;
(8) Zolpidem; and
(9) Zopiclone.
1205 SCHEDULE V ENUMERATED
1205.1 The following controlled substances listed below are included in Schedule V of the Act unless removed therefrom pursuant to Section 201 of the Act:
(a) Narcotic drugs containing non-narcotic active medicinal ingredients: Any compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or salts thereof, that also contains one (1) or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal quantities other than those possessed by the narcotic drug alone:
(1) Not more than two hundred (200) milligrams of codeine per one hundred (100) milliliters or per one hundred (100) grams;
(2) Not more than one hundred (100) milligrams of dihydrocodeine per one hundred (100) milliliters or per one hundred (100) grams;
(3) Not more than one hundred (100) milligrams of ethylmorphine per one hundred (100) milliliters or per one hundred (100) grams;
(4) Not more than two and five-tenths (2.5) milligrams of diphenoxylate and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;
(5) Not more than one hundred (100) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams;
(6) Not more than one half-tenth (0.5) milligrams of Difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;
(b) Propylhexedrine;
(c) Pyrovalerone; and
(g) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
(1) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]- carbamic acid ethyl ester];
(2) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy- propionamide]; and
(3) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].
